Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
NCT04872608 · Memorial Sloan Kettering Cancer Center · PHASE1 · withdrawn · last registry update 2023-04-28 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The sponsor closed the study due to discontinuing their onapristone program” | – | Registry record, Memorial Sloan Kettering Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYP19A1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-04-24Phase 3 first posted: AstraZeneca, Saruparib (AZD5305) + Camizestrant (NCT06380751)
- 2024-04-05Results posted on the registry: Novartis Pharmaceuticals, Ribociclib + Anastrozole (NCT03822468)
- 2024-03-27Results posted on the registry: Novartis Pharmaceuticals, Alpelisib + Fulvestrant (NCT03056755)
- 2024-01-25Phase 3 first posted: Region Örebro County, Letrozole + Anastrozole (NCT06223698)
- 2023-12-20Results posted on the registry: SWOG Cancer Research Network, anastrozole + everolimus (NCT01674140)
- 2023-12-05Results posted on the registry: Stemline Therapeutics, Inc., Elacestrant + Standard of Care (NCT03778931)
- 2023-08-31Results posted on the registry: Dana-Farber Cancer Institute, Letrozole + Tamoxifen (NCT02764541)
- 2023-08-30Phase 3 first posted: Olema Pharmaceuticals, Inc., Palazestrant + Fulvestrant (NCT06016738)
- 2023-08-24Phase 3 first posted: Tianjin Medical University Cancer Institute and Hospital, dalpiciclib、Exemestane、Gosserine + Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection (NCT06009627)
- 2023-08-21Results posted on the registry: University of Alabama at Birmingham, Letrozole + Everolimus (NCT02520063)
- 2023-07-19Phase 3 first posted: AstraZeneca, Camizestrant + Tamoxifen (NCT05952557)
- 2023-07-06Results posted on the registry: Sanofi, Amcenestrant-matching placebo + SAR439859 (NCT04478266)
- 2023-06-27Results posted on the registry: National Cancer Institute (NCI), Anastrozole + Exemestane (NCT01272037)
- 2023-06-18Phase 3 first posted: Pfizer, Vepdegestrant (ARV-471/PF-07850327) + Palbociclib (NCT05909397)
- 2023-06-08Phase 3 first posted: Hoffmann-La Roche, Inavolisib + Phesgo (NCT05894239)
- 2023-05-16Phase 3 first posted: Shanghai Pharmaceuticals Holding Co., Ltd, SPH4336 Tablets + SPH4336 Tablets Placebo (NCT05860465)
- 2023-04-24Phase 3 first posted: Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT05827081)
- 2023-03-30Results posted on the registry: Sanofi, Amcenestrant + Fulvestrant (NCT04059484)
- 2023-03-22Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen + Placebo capsules, Letrozole, Anastrozole, Tamoxifen (NCT05780567)
- 2023-03-20Phase 3 first posted: AstraZeneca, Camizestrant + Tamoxifen (NCT05774951)
- 2023-02-27Phase 3 first posted: Shanghai Pharmaceuticals Holding Co., Ltd, SPH4336 Tablets 400mg + SPH4336 Tablets Placebo (NCT05744687)
- 2022-12-09Phase 3 first posted: Tolmar Inc., TOL2506 + Tamoxifen (NCT05645536)
- 2022-10-18Results posted on the registry: Medical College of Wisconsin, Anastrozole + Letrozole (NCT03219476)
- 2022-09-29Results posted on the registry: Boehringer Ingelheim, Xentuzumab + Placebo (NCT03659136)
- 2022-08-24Phase 3 first posted: Eli Lilly and Company, Imlunestrant + Tamoxifen (NCT05514054)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision